Quitting Nicotine on a GLP-1: Can It Stop Post-Quit Weight Gain?
Possibly, but it hasn't been proven. Untreated quitters gain about 10 pounds on average in the first year, and early trials suggest GLP-1 drugs can blunt that gain. No GLP-1 is approved to help you quit, though. The proven quit tools are still nicotine replacement, varenicline and bupropion, and a GLP-1 can sit alongside them if your prescriber agrees.
Key takeaways
- A BMJ meta-analysis found untreated quitters gained an average of 4.67 kg (about 10 lb) at 12 months, with most of it in the first three months.
- In a small 2021 pilot trial, exenatide plus a nicotine patch led to 5.6 lb less post-quit weight than patch plus placebo.
- A 2026 semaglutide trial in smokers reduced craving and body weight but did not significantly cut cigarettes per day.
- No GLP-1 has an FDA indication for quitting tobacco. Every trial so far studied cigarette smokers, not vapers, dippers or pouch users.
- Varenicline and GLP-1s both cause nausea, so stacking them needs a plan with your prescriber.
How much weight men actually gain after quitting
The fear is not irrational. The most cited analysis, a 2012 BMJ meta-analysis by Aubin and colleagues, tracked people who quit smoking without any cessation medicine.
| Time after quitting | Average weight gain | Approx. pounds |
|---|---|---|
| 1 month | 1.12 kg | 2.5 lb |
| 3 months | 2.85 kg | 6.3 lb |
| 6 months | 4.23 kg | 9.3 lb |
| 12 months | 4.67 kg | 10.3 lb |
Source: Aubin et al., BMJ 2012. Pound conversions rounded.
The average hides a wide spread. At 12 months, about 16% of quitters had lost weight, while about 13% had gained more than 10 kg (22 lb). Most of the gain came in the first three months. A later BMJ Open paper summarizes the literature similarly: most quitters gain weight, often 5 to 15 lb in the first few months, and worry about that gain stops some people from trying to quit at all.
That early window is exactly where a GLP-1, which works largely by cutting appetite, could in theory help.
What the GLP-1 quit-smoking trials show
Exenatide plus the patch (2021 pilot)
The clearest data come from a pilot randomized trial by Yammine and colleagues in Nicotine & Tobacco Research. It enrolled 84 smokers with prediabetes and/or overweight. Everyone got a nicotine patch; half also got weekly exenatide, an older GLP-1 drug, and half got placebo, for six weeks.
| Outcome | Exenatide + patch | Placebo + patch |
|---|---|---|
| Not smoking at end of treatment | 46.3% (19 of 41) | 26.8% (11 of 41) |
| Post-quit weight | 5.6 lb lower with exenatide | |
| Adverse events (all mild) | 9.5% | 2.3% |
Source: Yammine et al., Nicotine & Tobacco Research, 2021.
Encouraging, but small. The statistical range for the quit-rate benefit included no effect at all, treatment lasted only six weeks, and the craving reduction was not clinically meaningful in the full results. The same team then launched a larger 216-person trial of once-weekly exenatide 2 mg plus a patch for 14 weeks, starting two weeks before quit day (registered as NCT05610800). Its published protocol listed an estimated primary completion date of March 31, 2026, so results may appear soon.
Semaglutide in daily smokers (2026)
A phase 2a trial published in JAMA Network Open in 2026 (full text) randomized 24 daily smokers who were not trying to quit to semaglutide or placebo for about nine weeks, reaching 1 mg. According to ReachMD's summary:
- Neither co-primary lab smoking outcome reached significance, and cigarettes per day did not change significantly versus placebo.
- Craving fell more on semaglutide.
- Weight changed by -5.11% on semaglutide vs. +1.58% on placebo through week 10.
- Side effects were mostly mild and gastrointestinal.
The investigators called the results "early and hypothesis-generating rather than evidence of long-term efficacy, safety, or cessation benefit." Worth noting for this site's readers: 83% of participants were women, so the trial says little about men specifically.
Real-world data
A target trial emulation in Annals of Internal Medicine looked at people with type 2 diabetes and tobacco use disorder. Starting semaglutide was associated with fewer tobacco-related medical visits than starting insulin (hazard ratio 0.68) or other GLP-1 drugs (0.88), (Annals of Internal Medicine). It's observational and didn't measure whether people actually quit, so treat it as a lead, not proof.
Other semaglutide studies are registered, including one titled Semaglutide for Post-Smoking Cessation Weight Management. Registration is not a result.
Compare available care options
If you qualify for a GLP-1 on its own merits, a licensed prescriber can factor in a quit plan; a consult is not a prescription guarantee.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
What is not proven
- No approval. Exenatide, semaglutide and tirzepatide are approved for diabetes, weight management and related conditions, not tobacco cessation. Prescribing one to quit smoking alone would be off-label.
- Quit rates. No trial has yet shown, with adequate size, that a GLP-1 raises long-term quit rates.
- Vapes, dip and pouches. The trials above enrolled cigarette smokers. There's no trial evidence for e-cigarette, smokeless tobacco or nicotine pouch users, and the USPSTF notes evidence gaps even for standard treatments in non-cigarette tobacco.
- Tirzepatide. None of the studies above tested it.
The proven quit tools, and how a GLP-1 fits
The USPSTF gives an A grade to clinicians asking adults about tobacco, advising them to quit, and providing behavioral support plus FDA-approved medicine. It found the evidence insufficient to recommend e-cigarettes as a quit tool. FDA's list of approved options covers:
- Nicotine patches, gum and lozenges (over the counter).
- Nicotine nasal spray and inhaler (prescription).
- Varenicline and bupropion tablets (prescription).
A GLP-1 is not a substitute for any of these. The realistic role, if your prescriber thinks you qualify for one anyway (for obesity, diabetes, sleep apnea or heart risk), is to help with the weight side while the proven tools handle the nicotine side. In the exenatide trials, everyone was also on a patch.
Why timing matters: the first three months
The Aubin data show where the risk is concentrated. Of the 4.67 kg average gain at one year, 2.85 kg, roughly 60%, had already arrived by month three. Any tool aimed at post-quit weight has to be working during that window.
That's a problem for a man who starts a GLP-1 and quits on the same day. These drugs begin at low doses and step up over weeks; in the 2026 semaglutide trial, participants went from 0.25 mg to 0.5 mg to 1 mg over nine weeks, and exploratory analyses found larger effects on withdrawal, self-efficacy and readiness to change in weeks 5 to 8 than in weeks 1 to 4. The larger exenatide trial deliberately started the drug two weeks before quit day and continued it for 12 weeks after.
None of this tells you the right sequence for your own plan. It does explain why the order of operations, which drug first and when to set the quit date, deserves its own conversation with your prescriber rather than an afterthought.
Stacking nausea: varenicline, NRT and a GLP-1
The biggest practical problem with combining them is your stomach.
| Drug | Nausea on drug | Nausea on placebo |
|---|---|---|
| Varenicline 1 mg twice daily | 30% | 10% |
| Wegovy 2.4 mg weekly | 44% | 16% |
Sources: Chantix (varenicline) prescribing information; Wegovy prescribing information.
The varenicline label adds that combining it with a nicotine patch increased nausea, headache, vomiting, dizziness, indigestion and fatigue compared with the patch alone. It says to take varenicline after eating with a full glass of water. Neither label offers guidance on using varenicline and a GLP-1 together, so the timing is something to work out with your prescriber. The Wegovy label also warns that vomiting and diarrhea can cause dehydration and kidney problems, and that semaglutide delays stomach emptying.
Questions to bring to your prescriber
- Do I qualify for a GLP-1 on its own merits, apart from quitting?
- Should I settle into a stable GLP-1 dose before my quit date, or start them together?
- How do we avoid a dose increase landing in the same week I start varenicline?
- Would a patch plus short-acting nicotine (gum or lozenge) be easier on my stomach than varenicline?
- I vape, dip or use pouches rather than smoke. What does the evidence say for my situation?
- What should I do if nausea gets bad enough that I'm not keeping fluids down?
Where this guide stops
This article summarizes published trials, US labels and federal guidance as of October 2026. It doesn't tell you which quit medicine to use or at what dose; that depends on your health history and should be decided with a clinician. The trials above are small, and future results could change the picture. Compounded GLP-1s are not FDA-approved and weren't used in any of these studies.
Talk to a licensed prescriber
Compare telehealth options for FDA-approved GLP-1s and check each provider's terms directly before you sign up.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
How much weight do people gain after quitting smoking?
A 2012 BMJ meta-analysis found untreated quitters gained an average of 4.67 kg (about 10 lb) at 12 months, with most of it in the first three months. About 16% lost weight and about 13% gained more than 10 kg.
Can a GLP-1 prevent weight gain after quitting smoking?
Early evidence suggests it may help. In a small pilot trial, exenatide plus a nicotine patch led to 5.6 lb less post-quit weight than patch plus placebo, but larger trials are still needed.
Is any GLP-1 approved to help you quit smoking?
No. FDA-approved cessation options are nicotine replacement products, varenicline and bupropion. Using a GLP-1 for quitting alone would be off-label.
Can I take Chantix (varenicline) with Wegovy or Zepbound?
Neither label gives guidance on the combination. Both commonly cause nausea (30% on varenicline and 44% on Wegovy 2.4 mg in trials), so plan timing and dose changes with your prescriber.
Does this apply to vaping, dip or nicotine pouches?
The GLP-1 trials so far enrolled cigarette smokers only, so there's no trial evidence for vapers, smokeless tobacco or pouch users.
Sources
- Aubin et al. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ 2012
- Yammine et al. Exenatide as an adjunct to nicotine patch: study protocol. BMJ Open 2023
- Yammine et al. Exenatide adjunct to nicotine patch: pilot RCT. Nicotine & Tobacco Research 2021
- ClinicalTrials.gov: NCT05610800, Exenatide for Smoking Cessation and Prevention of Weight Gain
- Once-weekly semaglutide in adults with daily cigarette use: a randomized clinical trial. JAMA Netw Open 2026 (PMC full text)
- ReachMD: Once-weekly semaglutide for daily cigarette use, trial results (Jun 2026)
- Annals of Internal Medicine: semaglutide and tobacco use disorder in patients with type 2 diabetes, a target trial emulation (doi:10.7326/M23-2718)
- ClinicalTrials.gov: NCT06173778, Semaglutide for Post-Smoking Cessation Weight Management
- USPSTF: Tobacco Smoking Cessation in Adults (2021)
- FDA: Want to quit smoking? FDA-approved and FDA-cleared cessation products
- DailyMed: Chantix (varenicline) prescribing information
- DailyMed: Wegovy (semaglutide) prescribing information
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.